Identi Healthcare Ltd
IDNT.TA
Tel Aviv Stock Exchange182.10
ILA
+6.50
- -
ISIN
IL0011774507
Return %
Stock
S&P500
1Y
-15.58
26.84
3Y
-46.20
77.03
5Y
-78.53
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shlomo Matityaho
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- Building 9 Netanya Israel 4250437
- IPO Date
- Jun 24, 2021
- Website
- identimedical.com
- Similar Companies
- Business
- Identi Healthcare Ltd (TASE: IDNT.TA) develops and markets innovative medical devices for wound care and tissue regeneration. The company offers a portfolio of advanced bioactive wound dressings, including proprietary technologies such as Identimed's collagen-based matrices and hydrogel systems designed for chronic wounds, burns, and surgical sites; skin substitutes for full-thickness wounds; and antimicrobial barrier dressings to prevent infection; alongside complementary services like clinical training and distribution partnerships for healthcare providers. Founded in 2008 and headquartered in Caesarea, Israel, Identi Healthcare primarily serves hospitals, clinics, and home care settings in Europe, the Middle East, and North America, with a focus on dermatology, vascular surgery, and diabetic foot care segments. In late 2024, the company completed a strategic rebranding from Identimed Ltd to Identi Healthcare Ltd to better reflect its expanded focus on integrated healthcare solutions and completed a NIS 25 million funding round led by institutional investors to support product commercialization and market expansion into Asia; additionally, it launched the IDNT-Advanced Regen matrix, a next-generation tissue engineering product, and formed a distribution alliance with a major European medtech distributor in Q3 2025.